Andromeda Biotech: A drug for type 1 diabetes

Developed by Proffessor Irun Cohen of the Weizmann Institute meets primary and secondary goals of phase 3 clinical trials

2011-11-23

(Press-News.org) The clinical trial was random, regulated, double-blinded and broad-based. The drug was tested on 457 patients, aged 16-45, who had been diagnosed with Type 1 diabetes a short time before joining the trial. The trial took place in around 40 medical centers in Europe, Israel and South Africa. The patients in the trial were randomly assigned to one of two groups: One received the trial drug (DiaPep277®) through a subcutaneous injection once every three months, for a period of two years, while the control group was given a placebo in the same way. In addition, all of the patients received insulin as needed to stabilize their glucose levels.

DiaPep277® was invented by Prof. Irun Cohen and his team at the Weizmann Institute of Science. This unique peptide, containing 24 amino acids, is derived from the sequence of the human heat shock protein 60 (Hsp60). The peptide acts by modulating the immune system, preventing the destruction of the pancreatic cells that secrete insulin and preserving their natural function. Treatment of Type 1 diabetes patients with DiaPep277® may have several medical benefits: slowing the deterioration of the diseased tissue, improved metabolic control, a reduction in daily insulin requirements and fewer complications of diabetes.

During the trial, the ability of the patients' pancreas to secrete insulin was tested. From an initial analysis of the results, it appears that the patients treated with the drug for a year or more had significantly higher pancreas function than those in the control group.

From the point of view of safety, no significant differences were found in the incidence of side effects between the treated and control groups.

Additional data on the drug's efficacy and safety were collected and evaluated, and these will be presented in a final report on the trial, which will be completed in several months.

Andromeda Biotech is now planning to conduct another trial, to try to reproduce these results. Recruitment of patients into this trial is expected to be finalized in the second quarter of 2012. The research and development team of Andromeda Biotech emphasize that the drug is still under development, and there is no absolute guarantee that the drug will eventually be marketed.

###Prof. Irun Cohen's research is supported by the Laszlo N. Tauber Family Foundation

The Weizmann Institute of Science in Rehovot, Israel, is one of the world's top-ranking multidisciplinary research institutions. Noted for its wide-ranging exploration of the natural and exact sciences, the Institute is home to 2,700 scientists, students, technicians and supporting staff. Institute research efforts include the search for new ways of fighting disease and hunger, examining leading questions in mathematics and computer science, probing the physics of matter and the universe, creating novel materials and developing new strategies for protecting the environment.

Weizmann Institute news releases are posted on the World Wide Web at http://wis-wander.weizmann.ac.il, and are also available at http://www.eurekalert.org.

ELSE PRESS RELEASES FROM THIS DATE:

Happy, feel-good holiday seasons start with healthy choices at Thanksgiving, nutrition experts say

2011-11-23

COLUMBIA, Mo. – While most people only gain about a pound of weight during the holiday season, that pound may never come off, increasing the likelihood of becoming overweight or obese and the risk of related health problems, according to a National Institutes of Health study. University of Missouri dietitians recommend families maintain healthy diet and exercise habits during the holiday season beginning with Thanksgiving. Donna Mehrle, registered dietitian and extension associate in the Department of Nutrition and Exercise Physiology, reminds people to consider ...

Maryland Man Faces Life Imprisonment for Child Pornography Charge

2011-11-23

Authorities Break Up Maryland Child Pornography Ring In June, a Maryland man pled guilty to one count of interstate advertisement of child pornography. The man used a friend-sharing program to establish a child pornography network that shared over 10,000 images and photos of young boys with over 70 "buddies." Everyone in the network was encouraged to manufacture "fresh" material for the group. Those who did not were threatened with being kicked out. According to statements made by the man, he spent several hours a day making new videos for the ...

The impending revolution of low-power quantum computers

2011-11-23

By 2017, quantum physics will help reduce the energy consumption of our computers and cellular phones by up to a factor of 100. For research and industry, the power consumption of transistors is a key issue. The next revolution will likely come from tunnel-FET, a technology that takes advantage of a phenomenon referred to as "quantum tunneling." At the EPFL, but also in the laboratories of IBM Zurich and the CEA-Leti in France, research is well underway. As part of a special issue of Nature devoted to silicon, Adrian Ionescu, an EPFL researcher, has written an article on ...

"Sexting" and Internet Crimes in Colorado

2011-11-23

With the prevalence and speed of the Internet and mobile devices, racy photos and conversation are often shared via email, chat or text. Colorado has tough legislation that targets sexual exploitation of children that occurs over electronic media. Internet sex crimes have gained notoriety following various political scandals. In a recent case, a 37-year-old Colorado Springs school board member was accused of sending text messages to a 14-year-old boy. The text messages discovered by the boy's sister were sexual in nature and referenced oral sex. The messages started ...

Herbicide may affect plants thought to be resistant

2011-11-23

WEST LAFAYETTE, Ind. - Purdue University researchers have discovered a fine-tuning mechanism involved in plant root growth that has them questioning whether a popular herbicide may have unintended consequences, causing some plants to need more water or nutrients. Angus Murphy, a professor of horticulture, and Wendy Peer, an assistant professor of horticulture, study the movement of auxin, a plant hormone essential for plant development. They showed that ABCB4, a protein responsible for moving auxin into cells, also removes the hormone when too much has accumulated. "We ...

Depression and anxiety not linked to delayed resolution of abnormal mammograms, Pap tests

2011-11-23

Boston – In what is believed to be the first study of its kind to examine the relationship between pre-existing depression (with and without anxiety) and the amount of time to diagnostically resolve an abnormal mammogram and/or Pap test, researchers from Boston University School of Medicine (BUSM) have found suffering from depression was not associated with a prolonged time to diagnostic resolution in a vulnerable population of urban women. These findings currently appear in the Journal of General Internal Medicine. Delays in care after abnormal cancer screenings contribute ...

Olinsky Law Group Donates $100,000 to Burton Blatt Institute at Syracuse University

2011-11-23

In support of the Burton Blatt Institute (BBI) at Syracuse University, Howard D. Olinsky, L'85, a disability law attorney representing clients across the country, has announced a commitment of $100,000 to BBI, one of the institute's most generous private donations. "This fantastic gift will help ensure that BBI builds the next generation of young leaders by supporting fellowships for law students to positively impact people with disabilities," said University Professor Peter Blanck, BBI chairman. "Howard's commitment is a perfect example of an investment ...

Olympic Villages: Catalyst for urban renewal, or post-Games hangover?

2011-11-23

The Olympic Games are big business and generate substantial amounts of revenue for the International Olympic Committee (IOC) through lucrative television contracts and corporate sponsorship. The Games are now also widely perceived as important promotional opportunities for cities seeking to reinforce their claims as 'world class' destinations for tourists and capital in the global economy. Related to these latter goals, beginning with the 1992 Barcelona Olympics, the Games have also been envisioned by civic elites as opportunities to develop under-utilized land through ...

Arginine restores T-cell ability to target cancer

2011-11-23

In many cases, tumors suppress a patient's immune system in a way that keeps the cancer safe from immune system attack. This is particularly true for patients with glioblastoma, a primary brain tumor that carries a prognosis of only 12-15 months survival after diagnosis. A study at the University of Colorado Cancer Center, recently published as a featured article in the journal Clinical Cancer Research, shows that treatment with the over-the-counter amino acid arginine may reactivate cancer-fighting T-cells in patients with glioblastoma, thus potentially allowing the ...

Schachter Harris Wins Garlock Sealing Technologies Case

2011-11-23

We represented Garlock Sealing Technologies, LLC in an appeal of a judgment against Garlock entered by the US District Court in Louisville, Kentucky. The United States Court of Appeals for the Sixth Circuit reversed the judgment and effectively rendered judgment against the plaintiff in Garlock's favor. The plaintiff, Olwen Moeller, individually and as executrix for the estate of Robert L. Moeller, sued Garlock alleging Mr. Moeller's work as a pipefitter with asbestos-containing gaskets made by Garlock were a substantial cause of his mesothelioma. Plaintiff supported ...

nTIDE March 2025 Jobs Report: Employment rate for people with disabilities holds steady at new plateau, despite February dip

While most Americans strongly support civics education in schools, partisan divide on DEI policies and free speech on college campuses remains

Revolutionizing surface science: Visualization of local dielectric properties of surfaces

[Press-News.org] Andromeda Biotech: A drug for type 1 diabetes
Developed by Proffessor Irun Cohen of the Weizmann Institute meets primary and secondary goals of phase 3 clinical trials

Andromeda Biotech: A drug for type 1 diabetes

ELSE PRESS RELEASES FROM THIS DATE:

LAST 30 PRESS RELEASES: